Komori
Rohto Pharmaceutical (4527) · PolicyAdvanced

Management Focused on Profitability Metrics

First written in FY2017. 6 of 8 entries say "Advanced", first in FY2020. Latest entry: FY2026.

8entries
10years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017AdvancedFY2020 – 2026-06-012017: 120172018: 020182019: 020192020: 120202021: 020212022: 020222023: 120232024: 120242025: 020252026: 42026
Same theme, other companies
Profitability metric management using operating margin, ROE, ROA and EBITDAA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「We manage the business with a focus on profitability metrics, including revenue, operating margin, return on equity, return on assets based on ordinary profit and EBITDA margin.」

    The company continues its policy of focusing on profitability metrics and has newly presented targets for FY2030, including revenue of ¥415.0 billion, operating profit of ¥54.0 billion, an operating margin of 13.0% and an EBITDA margin of 18.2%.
  2. FY2024AdvancedAnnual report

    「The target for the metric used for performance-linked compensation in the fiscal year was ¥40,000 million, compared with an actual result of ¥40,048 million.」

    Under its management approach focused on profitability metrics, actual operating profit was ¥40,048 million against a target of ¥40,000 million. Return on equity has been maintained at 13.6%.
  3. FY2023AdvancedAnnual report

    「Return on equity (%) 7.6 11.4 11.7 12.7 13.6」

    Under its management policy of focusing on profitability metrics, the company reports FY2023 return on equity of 13.6% and operating profit of ¥33,959 million. It also reports actual operating profit of ¥33,959 million against the ¥33,000 million operating profit target for performance-linked compensation.
  4. FY2020AdvancedAnnual report

    「As revenue and profit increased, operating margin improved significantly to 12.3% (11.3% in the same period of the previous year) and return on equity to 11.4% (7.6%).」

    The company reports full-year results of a 12.3% operating margin and 11.4% return on equity under its management policy of focusing on profitability metrics. Actual operating profit was ¥23,085 million, compared with an operating profit target of ¥21,500 million for performance-linked compensation.
  5. FY2017First statedAnnual report

    「We manage the business with a focus on profitability metrics such as operating margin, return on equity and ordinary profit to total assets.」

    To maximise shareholder value and improve stakeholder satisfaction, the company has for the first time presented as a standalone theme its management policy of focusing on profitability metrics, including operating margin, return on equity and return on assets based on ordinary profit.
Moved together

"Establishing a market position through high-value-added products and new brands" moved the same way as this thread, in the same document, in 5 of its 8 moves.

555544★123456
  1. ★This thread
  2. 1Establishing a market position through high-value-added products and new brands5×
  3. 2Technological Innovation and Strengthening the R&D Platform5×
  4. 3Globalization Centered on Asia and Expansion into Emerging Markets5×
  5. 4Capital investment in production facilities and research and development functions5×
  6. 5Strengthening Management Oversight by Outside Directors4×
  7. 6Strategic Shareholdings Held to Maintain and Develop Business Relationships4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet. It last moved in the General Meetings of Shareholders of 2026-06-16: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.